Anaptysbio Inc Stock Price, News & Analysis

Anaptys (Nasdaq: ANAB) announced an amended $100.0 million stock repurchase plan, in addition to $6.4 million remaining under the prior $75.0 million plan.

The company previously repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before that repurchase program. Purchases may occur in open market transactions or under Rule 10b5-1/10b-18 programs.

Anaptys expects to end 2025 with approximately $300 million in cash, cash equivalents and investments, which includes an anticipated one-time $75 million commercial sales milestone from GSK tied to Jemperli reaching $1 billion in worldwide net sales. The repurchase plan expires March 31, 2026 and may be suspended or discontinued at any time; it does not obligate any repurchases.

Anaptys (Nasdaq: ANAB) reported that its Phase 2 trial of rosnilimab in moderate-to-severe ulcerative colitis did not meet the Week 12 primary endpoint (mean change in modified Mayo Score) or key secondary endpoints of clinical response and remission; the UC trial will be discontinued.

Rosnilimab was well tolerated with no new safety signals and showed ~90% depletion of pathogenic T cells in blood and PD-1+ T cell depletion in colon at Week 12. Discontinuing UC will save at least $10 million. Company expects to end 2025 with approximately $300 million, including a one-time $75 million GSK milestone in Q4 2025 tied to Jemperli sales, and plans to pursue rosnilimab in RA with an H1 2026 update and to separate biopharma operations from royalty assets in 2026.

Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.

Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.

Anaptys (Nasdaq: ANAB) reported Q3 2025 results and announced intent to separate its biopharma operations from its royalty management business by year-end 2026 to unlock value across two public companies. The company expects to accrue a one-time $75 million commercial milestone in Q4 2025 when GSK's Jemperli reaches $1 billion in worldwide sales and cites >$390 million in annualized royalties at GSK peak-sales guidance of >$2.7 billion.

Operationally, Anaptys highlighted rosnilimab Phase 2b RA data and expects top-line Week-12 UC Phase 2 data in Nov/Dec 2025; ANB033 Phase 1b in celiac initiated with data expected in Q4 2026. Cash and investments were $256.7 million at Sept 30, 2025, with ~3.34M shares repurchased (~10.9% outstanding) for $65.2 million.

Anaptys (Nasdaq: ANAB) reported late-breaking Phase 2b results for rosnilimab in rheumatoid arthritis on Oct 29, 2025, from a global 424-patient trial presented at ACR Convergence 2025. Primary Week 12 efficacy on DAS28-CRP and ACR20 was confirmed and responses deepened by Week 28, including CDAI low disease activity and CDAI remission, independent of prior advanced therapies including JAK inhibitors.

Responses remained durable for at least three months off drug. Safety through Week 38 showed rosnilimab was well-tolerated with no treatment-related serious adverse events, no malignancies, and no deaths; Tph cells were reduced by >90% by Week 6.

Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented as a late-breaking oral at ACR Convergence 2025 in Chicago on Oct 29, 2025 from 8:00–9:30am CT.

The company described rosnilimab as a pathogenic T cell depleter that produced a compelling safety and tolerability profile and JAK-like efficacy through six months, with effects that were reported as durable for at least three months off-drug. Paul Emery, M.D., University of Leeds, will present (Abstract ID 2215555). The presentation will be available for download from the company website after the session.

AnaptysBio (NASDAQ:ANAB) announced a virtual investor event scheduled for October 14, 2025, at 4:30 PM ET to discuss ANB033, their CD122 antagonist therapeutic candidate. The presentation will feature Dr. Joseph A. Murray from Mayo Clinic alongside the company's management team.

The event will cover three key areas: ANB033's mechanism of action as a CD122 receptor antagonist, preclinical and initial Phase 1a data from healthy volunteers, and celiac disease biology along with Phase 1b trial design. A Q&A session will follow the presentation, with a live webcast available on the company's investor relations website.

AnaptysBio (NASDAQ:ANAB) announced plans to split into two independent, publicly traded companies by year-end 2026. The first entity, temporarily named Royalty Management Co, will manage royalties from collaborations including GSK's Jemperli (generating $482M in 1H 2025) and Vanda's imsidolimab. The second entity, Biopharma Co, will focus on developing immunology therapeutics, including rosnilimab, ANB033, and ANB101.

Key financials include Jemperli's tiered royalties of 8-25% on net sales, with GSK projecting peak sales of £2 billion ($2.7B). The Vanda collaboration could yield up to $35M in milestones plus 10% royalties. Current Jemperli royalties are directed to Sagard until reaching $600M by 2031 or $675M thereafter, with an estimated $250M accrued through 2025.